AMLX Projected Dividend Yield
Amylyx Pharmaceuticals Inc ( NASDAQ : AMLX )Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. Co. is engaged in the discovery and development of treatments for neurodegenerative diseases. Co. is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Co.'s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). 21 YEAR PERFORMANCE RESULTS |
AMLX Dividend History Detail AMLX Dividend News AMLX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |